moxifloxacin has been researched along with Escherichia coli Infections in 18 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 12 (66.67) | 29.6817 |
| 2010's | 5 (27.78) | 24.3611 |
| 2020's | 1 (5.56) | 2.80 |
| Authors | Studies |
|---|---|
| Arakawa, Y; Kato, H; Kimura, K; Konda, T; Shibata, N; Shibayama, K; Suzuki, S; Wachino, J; Yamane, K | 1 |
| Cattoir, V; Nordmann, P; Poirel, L | 1 |
| Al-Trawneh, SA; Alfieri, RR; Cavazzoni, A; El-Abadelah, MM; Incerti, M; Kamal, MR; Petronini, PG; Vicini, P; Zahra, JA; Zani, F | 1 |
| Gou, C; Li, C; Li, XZ; Li, YR; Liu, HY; Liu, JC; Piao, HR; Zhang, ML; Zheng, CJ | 1 |
| Graue-Hernandez, EO; Lichtinger, A; Navas, A; Polania-Baron, EJ; Santana-Cruz, O | 1 |
| Chang, KT; Hou, JG; Ledesma, KR; Prince, RA; Singh, R; Tam, VH | 1 |
| Chandra, S; Chattopadhyay, S; De, K; Ganguly, S; Mishra, M; Ranjan Sarkar, B; Saha Das, S; Sinha, S | 1 |
| Aracil, B; Campos, J; Cuevas, O; de Abajo, F; García-Cobos, S; Lázaro, E; Ortega, A; Oteo, J | 1 |
| Baud, O; Bidet, P; Bingen, E; Biran, V; Bonacorsi, S; Brunel-Meunier, N; Charriaut-Marlangue, C; Gressens, P; Kitzis, MD; Le Saché, N; Pansiot, J; Pham, H | 1 |
| Braun, J; Dirnagl, U; Halle, E; Megow, D; Meisel, A; Meisel, C; Prass, K; Victorov, I; Volk, HD; Wolf, T | 1 |
| Ackermann, G; Beer, J; Blatz, R; Rodloff, AC; Schaumann, R | 1 |
| Bouros, DE; Kottakis, I; Liapakis, IE; Light, RW; Pitiakoudis, MS; Simopoulos, CE; Tsatsakis, AM; Tzatzarakis, MN; Ypsilantis, P | 1 |
| Hermsen, ED; Hovde, LB; Rodvold, KA; Rotschafer, JC; Sprandel, KA | 1 |
| Forberg, J; Goldstein, EJ; Rodloff, AC; Schaumann, R | 1 |
| Ader, F; Bernard, L; Carlier, R; Perronne, C; Salomon, J; Toubiana, J | 1 |
| Cars, O; Odenholt, I | 1 |
| Denizbasi, A; Erdede, M; Guneysel, O; Onur, O | 1 |
| Barzilai, A; Diamantstein, L; Gruzman, G; Keller, N; Rubinovitch, B; Rubinstein, E; Yoseph, G | 1 |
18 other study(ies) available for moxifloxacin and Escherichia coli Infections
| Article | Year |
|---|---|
New plasmid-mediated fluoroquinolone efflux pump, QepA, found in an Escherichia coli clinical isolate.
Topics: Amino Acid Sequence; Anti-Bacterial Agents; Carbonyl Cyanide m-Chlorophenyl Hydrazone; Chitosan; Conjugation, Genetic; DNA, Bacterial; Drug Resistance, Bacterial; Escherichia coli; Escherichia coli Infections; Fluoroquinolones; Humans; Malates; Microbial Sensitivity Tests; Molecular Sequence Data; Plasmids; Reverse Transcriptase Polymerase Chain Reaction; Transformation, Bacterial; Uncoupling Agents | 2007 |
Plasmid-mediated quinolone resistance pump QepA2 in an Escherichia coli isolate from France.
Topics: Aged; Base Sequence; DNA Primers; DNA, Bacterial; Drug Resistance, Bacterial; Escherichia coli; Escherichia coli Infections; Escherichia coli Proteins; Female; Fluoroquinolones; France; Genes, Bacterial; Humans; Models, Genetic; Molecular Sequence Data; Plasmids | 2008 |
Synthesis and biological evaluation of tetracyclic fluoroquinolones as antibacterial and anticancer agents.
Topics: Anti-Bacterial Agents; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cell Death; Cell Line; Cell Line, Tumor; DNA Gyrase; DNA Topoisomerase IV; Escherichia coli; Escherichia coli Infections; Female; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Topoisomerase II Inhibitors | 2010 |
Synthesis and antimicrobial evaluation of 5-aryl-1,2,4-triazole-3-thione derivatives containing a rhodanine moiety.
Topics: Anti-Infective Agents; Candida albicans; Candidiasis; Escherichia coli; Escherichia coli Infections; Humans; Rhodanine; Staphylococcal Infections; Staphylococcus aureus; Thiones; Triazoles | 2015 |
Treatment of Severe Infectious Keratitis With Scleral Contact Lenses as a Reservoir of Moxifloxacin 0.5.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Aspergillosis; Contact Lenses; Corneal Ulcer; Drug Carriers; Escherichia coli Infections; Eye Infections, Bacterial; Eye Infections, Fungal; Female; Humans; Male; Middle Aged; Moxifloxacin; Prospective Studies; Pseudomonas Infections; Sclera; Staphylococcal Infections; Visual Acuity; Young Adult | 2021 |
Pharmacodynamics of moxifloxacin against a high inoculum of Escherichia coli in an in vitro infection model.
Topics: Anti-Bacterial Agents; Aza Compounds; Colony Count, Microbial; DNA Gyrase; DNA Mutational Analysis; DNA Topoisomerase IV; Drug Resistance, Bacterial; Escherichia coli; Escherichia coli Infections; Escherichia coli Proteins; Fluoroquinolones; Humans; Models, Theoretical; Moxifloxacin; Quinolines; Sequence Analysis, DNA | 2009 |
Synthesis and evaluation of (99m)Tc-moxifloxacin, a potential infection specific imaging agent.
Topics: Animals; Anti-Infective Agents; Aza Compounds; Escherichia coli Infections; Feasibility Studies; Fluoroquinolones; Image Enhancement; Isotope Labeling; Metabolic Clearance Rate; Moxifloxacin; Organ Specificity; Positron-Emission Tomography; Quinolines; Rabbits; Radiopharmaceuticals; Rats; Rats, Wistar; Technetium; Tissue Distribution | 2010 |
Significant ecological impact on the progression of fluoroquinolone resistance in Escherichia coli with increased community use of moxifloxacin, levofloxacin and amoxicillin/clavulanic acid.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin-Potassium Clavulanate Combination; Aza Compounds; Bacteremia; Drug Resistance, Bacterial; Drug Utilization; Escherichia coli; Escherichia coli Infections; Female; Fluoroquinolones; Hospitals; Humans; Levofloxacin; Male; Middle Aged; Moxifloxacin; Ofloxacin; Quinolines; Spain; Young Adult | 2011 |
Effect of moxifloxacin combined with cefotaxime compared to cefotaxime-gentamicin combination on prevention of white matter damage associated with Escherichia coli sepsis in neonatal rats.
Topics: Animals; Animals, Newborn; Anti-Bacterial Agents; Aza Compounds; Cefotaxime; Escherichia coli Infections; Fluoroquinolones; Gentamicins; Leukoencephalopathies; Moxifloxacin; Quinolines; Rats; Rats, Sprague-Dawley; Sepsis | 2011 |
Preventive antibacterial treatment improves the general medical and neurological outcome in a mouse model of stroke.
Topics: Animals; Antibiotic Prophylaxis; Aza Compounds; Bacterial Infections; Body Weight; Disease Models, Animal; Dose-Response Relationship, Drug; Escherichia coli Infections; Fever; Fluoroquinolones; Gram-Positive Bacterial Infections; Hypothermia; Immune Tolerance; Male; Mice; Mice, Inbred Strains; Moxifloxacin; Opportunistic Infections; Pneumonia, Bacterial; Quinolines; Sepsis; Stroke; Survival Rate; Treatment Outcome | 2004 |
Effect of moxifloxacin versus imipenem/cilastatin treatment on the mortality of mice infected intravenously with different strains of Bacteroides fragilis and Escherichia coli.
Topics: Animals; Anti-Bacterial Agents; Aza Compounds; Bacteroides fragilis; Bacteroides Infections; Cilastatin; Cilastatin, Imipenem Drug Combination; DNA, Bacterial; Drug Combinations; Escherichia coli; Escherichia coli Infections; Female; Fluoroquinolones; Imipenem; Kidney; Liver; Mice; Mice, Inbred C57BL; Mice, Inbred DBA; Microbial Sensitivity Tests; Moxifloxacin; Quinolines; Reverse Transcriptase Polymerase Chain Reaction | 2004 |
Penetration of newer quinolones in the empyema fluid.
Topics: Animals; Anti-Bacterial Agents; Aza Compounds; Empyema, Pleural; Escherichia coli Infections; Fluoroquinolones; Levofloxacin; Male; Moxifloxacin; Ofloxacin; Pleural Effusion; Quinolines; Rabbits | 2004 |
Levofloxacin plus metronidazole administered once daily versus moxifloxacin monotherapy against a mixed infection of Escherichia coli and Bacteroides fragilis in an in vitro pharmacodynamic model.
Topics: Anti-Bacterial Agents; Aza Compounds; Bacteroides fragilis; Bacteroides Infections; Chromatography, High Pressure Liquid; Colony Count, Microbial; Escherichia coli; Escherichia coli Infections; Fluoroquinolones; Half-Life; Humans; Levofloxacin; Metronidazole; Microbial Sensitivity Tests; Models, Biological; Moxifloxacin; Ofloxacin; Quinolines | 2005 |
Activity of moxifloxacin against Bacteroides fragilis and Escherichia coli in an in vitro pharmacokinetic/pharmacodynamic model employing pure and mixed cultures.
Topics: Anaerobiosis; Aza Compounds; Bacteroides fragilis; Escherichia coli; Escherichia coli Infections; Fluoroquinolones; Microbial Sensitivity Tests; Models, Biological; Moxifloxacin; Quinolines | 2005 |
[Cervical spondylodiscitis: one pathogen may hide another].
Topics: Anti-Bacterial Agents; Antitubercular Agents; Aza Compounds; Cervical Vertebrae; Cholecystitis; Discitis; Disease Progression; Drug Therapy, Combination; Escherichia coli; Escherichia coli Infections; Ethambutol; Fluoroquinolones; France; Humans; Immobilization; Isoniazid; Male; Middle Aged; Morocco; Moxifloxacin; Mycobacterium tuberculosis; Pyrazinamide; Quinolines; Radiography; Rifampin; Tuberculosis, Spinal | 2006 |
Pharmacodynamics of moxifloxacin and levofloxacin against Streptococcus pneumoniae, Staphylococcus aureus, Klebsiella pneumoniae and Escherichia coli: simulation of human plasma concentrations after intravenous dosage in an in vitro kinetic model.
Topics: Animals; Anti-Infective Agents; Area Under Curve; Aza Compounds; Escherichia coli; Escherichia coli Infections; Fluoroquinolones; Horses; Humans; Injections, Intravenous; Klebsiella Infections; Klebsiella pneumoniae; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Pneumococcal Infections; Quinolines; Staphylococcal Infections; Staphylococcus aureus; Streptococcus pneumoniae | 2006 |
Trimethoprim/sulfamethoxazole resistance in urinary tract infections.
Topics: Adolescent; Adult; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Anti-Infective Agents, Urinary; Aza Compounds; Ceftriaxone; Drug Resistance, Microbial; Escherichia coli Infections; Female; Fluoroquinolones; Humans; Male; Middle Aged; Moxifloxacin; Quinolines; Retrospective Studies; Trimethoprim, Sulfamethoxazole Drug Combination; Urinary Tract Infections; Young Adult | 2009 |
The effect of albumin, globulin, pus and dead bacteria in aerobic and anaerobic conditions on the antibacterial activity of moxifloxacin, trovafloxacin and ciprofloxacin against Streptococcus pneumoniae, Staphylococcus aureus and Escherichia coli.
Topics: Albumins; Anti-Infective Agents; Aza Compounds; Ciprofloxacin; Escherichia coli; Escherichia coli Infections; Fluoroquinolones; Globulins; Gram-Positive Bacterial Infections; Humans; Microbial Sensitivity Tests; Moxifloxacin; Naphthyridines; Pneumococcal Infections; Quinolines; Staphylococcal Infections; Staphylococcus aureus; Streptococcus pneumoniae; Suppuration | 2000 |